 |
 Video: What is a Stock Split?
|
|
|
| Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor T-cells, are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment. UCART is a therapeutic product line that it is developing with its gene-editing platform to address unmet medical needs in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma and other types of cancers. According to our Cellectis SA stock split history records, Cellectis SA has had 0 splits. | |
|
Cellectis SA (CLLS) has 0 splits in our Cellectis SA stock split history database.
Looking at the Cellectis SA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cellectis SA shares, starting with a $10,000 purchase of CLLS, presented on a split-history-adjusted basis factoring in the complete Cellectis SA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
03/25/2015 |
|
| End date: |
04/29/2024 |
|
| Start price/share: |
$39.30 |
|
| End price/share: |
$2.56 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-93.49% |
|
| Average Annual Total Return: |
-25.92% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$651.24 |
|
| Years: |
9.10 |
|
|
|
|
|
